68Ga-DOTATATE PET for Localization of Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia
Who is this study for? Patients with tumor induced osteomalacia
What treatments are being studied? 68Ga-DOTATATE PET/CT
Status: Completed
Location: See location...
Intervention Type: Combination product
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
The researchers are trying to evaluate a newer imaging technique (Ga-DOTATATE PET/CT) to see if it is more sensitive to localize the source of the hormone, which has caused the low phosphate levels.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adults (18 years of age or older) seen at Mayo Clinic, Rochester for FGF23 mediated osteomalacia between 1/1/2000 and 1/30/2018 who provide informed consent to participate in the study.
Locations
United States
Minnesota
Mayo Clinic
Rochester
Time Frame
Start Date: 2019-01-31
Completion Date: 2023-10-31
Participants
Target number of participants: 18
Treatments
Experimental: 68Ga-DOTATATE PET/CT
Subjects will undergo imaging by 68Ga-DOTATATE PET/CT
Authors
Related Therapeutic Areas
Sponsors
Leads: Mayo Clinic